Biotech companies seeking to go public in the U.S. face a stiff test during the surging outbreak of the new coronavirus, which is dragging down the stock market as the risks to the broader economy become real. Goodwin’s Michael Bison, a partner in the firm’s Life Sciences group and Capital Markets practice, discusses the potential damage and issues IPO hopefuls will face moving forward while remaining optimistic. Read the article here.
In The Press
March 12, 2020